| 1 |
34751786 | Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. | 2022 May 4 |
1 |
| 2 |
34871844 | Synthesis and biological evaluation of novel PET tracers [18F]AG120 & [18F]AG135 for imaging mutant isocitrate dehydrogenase 1 expression. | 2022 Jan 1 |
3 |
| 3 |
35154988 | Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review. | 2022 Jan |
3 |
| 4 |
35190971 | Systemic Therapy for Chondrosarcoma. | 2022 Feb |
3 |
| 5 |
35198955 | The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma. | 2022 |
4 |
| 6 |
35259259 | FDA Approval Summary: Ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. | 2022 Mar 8 |
3 |
| 7 |
35296436 | Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. | 2022 Mar 13 |
3 |
| 8 |
35418865 | Ag120-Mediated Inhibition of ASCT2-Dependent Glutamine Transport has an Anti-Tumor Effect on Colorectal Cancer Cells. | 2022 |
4 |
| 9 |
35443108 | Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. | 2022 Apr 21 |
3 |
| 10 |
35460975 | IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. | 2022 |
2 |
| 11 |
35532213 | Ivosidenib Boosts Azacitidine's Effectiveness in AML. | 2022 May 9 |
1 |
| 12 |
33024987 | Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. | 2021 Apr 1 |
1 |
| 13 |
33119479 | Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. | 2021 Jan 1 |
4 |
| 14 |
33397455 | Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML. | 2021 Jan 4 |
1 |
| 15 |
33493146 | Biliary cancer: gateway to comprehensive molecular profiling. | 2021 Jan |
1 |
| 16 |
33493392 | Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies. | 2021 May |
1 |
| 17 |
33683991 | Ivosidenib: an investigational drug for the treatment of biliary tract cancers. | 2021 Apr |
1 |
| 18 |
33709779 | Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. | 2021 Jun |
3 |
| 19 |
33772143 | Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. | 2021 Nov |
1 |
| 20 |
33799004 | IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? | 2021 |
1 |
| 21 |
33822485 | PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. | 2021 Jun |
3 |
| 22 |
33832922 | Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling. | 2021 Apr |
4 |
| 23 |
33836133 | Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. | 2021 May |
8 |
| 24 |
33898313 | IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. | 2021 |
1 |
| 25 |
33932504 | Practical considerations in screening for genetic alterations in cholangiocarcinoma. | 2021 Sep |
1 |
| 26 |
34071627 | Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia. | 2021 May 28 |
1 |
| 27 |
34188585 | Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. | 2021 |
1 |
| 28 |
34313176 | Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome. | 2021 Dec |
2 |
| 29 |
34321251 | Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. | 2021 Oct |
3 |
| 30 |
34554208 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. | 2021 Nov 1 |
6 |
| 31 |
34626563 | Current and emerging therapies for advanced biliary tract cancers. | 2021 Nov |
1 |
| 32 |
34889359 | What to use to treat AML: the role of emerging therapies. | 2021 Dec 10 |
1 |
| 33 |
31028664 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. | 2020 Apr |
5 |
| 34 |
31841594 | Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. | 2020 Feb 13 |
5 |
| 35 |
31910380 | Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia. | 2020 Jan |
3 |
| 36 |
32055803 | Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia. | 2020 Jan |
2 |
| 37 |
32171892 | Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. | 2020 Jul |
1 |
| 38 |
32208957 | Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. | 2020 May 20 |
3 |
| 39 |
32296873 | Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. | 2020 May |
5 |
| 40 |
32306411 | Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. | 2020 Oct |
1 |
| 41 |
32380538 | Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. | 2020 May 12 |
2 |
| 42 |
32393603 | Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. | 2020 Aug 15 |
3 |
| 43 |
32416072 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. | 2020 Jun |
5 |
| 44 |
32530764 | Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. | 2020 Oct 10 |
2 |
| 45 |
32588467 | Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. | 2020 Nov |
5 |
| 46 |
32601974 | Treatment of Relapsed Acute Myeloid Leukemia. | 2020 Jun 29 |
3 |
| 47 |
32716208 | Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study. | 2020 Sep 1 |
6 |
| 48 |
32758465 | Ivosidenib for advanced IDH1-mutant cholangiocarcinoma. | 2020 Aug |
1 |
| 49 |
32758466 | Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply. | 2020 Aug |
1 |
| 50 |
32808831 | Evaluating ivosidenib for the treatment of acute myeloid leukemia. | 2020 Dec |
3 |